Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: A prospective cohort study (CRANE)

Rheumatology (United Kingdom)

Volumn 54, Issue 5, 2014, Pages 798-807

  Sugihara, Takahiko ^a   Ishizaki, Tatsuro ^b   Hosoya, Tadashi ^a,c   Iga, Shoko ^a   Yokoyama, Waka ^a,c,d   Hirano, Fumio ^a,c,d   Miyasaka, Nobuyuki ^c   Harigai, Masayoshi ^c,d  

^a Tokyo Metropolitan Institute of Gerontology   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^c Department of Medicine and Rheumatology ^*  (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Clinical practice; Elderly onset RA; Functional remission; Structural remission; Treat to target

Indexed keywords

ADALIMUMAB; BUCILLAMINE; ETANERCEPT; INFLIXIMAB; LIVER ENZYME; METHOTREXATE; TACROLIMUS; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

AGED; AORTA ANEURYSM; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL MYOSITIS; BACTERIAL PNEUMONIA; CAUSE OF DEATH; COHORT ANALYSIS; DAS28; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG FATALITY; ELDERLY ONSET RHEUMATOID ARTHRITIS; ENZYME BLOOD LEVEL; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEART DISEASE; HERPES ZOSTER; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; LOEFFLER PNEUMONIA; LOW DISEASE ACTIVITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYOSITIS; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHYSICAL DISABILITY; PLEURISY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PULMONARY CRYPTOCOCCOSIS; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL GASTROENTERITIS;

EID: 84929665696     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu395     Document Type: Article

References (50)

1. Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003;48:917-26.
2. van der Heijde DM, van Riel PL, van Leeuwen MA et al. Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. J Rheumatol 1991;18:1285-9.
3. Mueller RB, Kaegi T, Finckh A et al. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort. Rheumatology 2014;53:671-7.
4. Tutuncu Z, Reed G, Kremer J, Kavanaugh A. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis 2006;65:1226-9.
5. Bathon JM, Fleischmann RM, van der Heijde D et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006;33:234-43.
6. Koller MD, Aletaha D, Funovits J et al. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology 2009;48:1575-80.
7. Yamanaka H, Tohma S. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol 2006;16:75-6.
8. Deal CL, Meenan RF, Goldenberg DL et al. The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration. Arthritis Rheum 1985;28:987-94.
9. Pease CT, Bhakta BB, Devlin J, Emery P. Does the age of onset of rheumatoid arthritis influence phenotype?: a prospective study of outcome and prognostic factors. Rheumatology 1999;38:228-34.
10. Genevay S, Finckh A, Ciurea A et al. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a populationbased cohort study. Arthritis Rheum 2007;57:679-85.
11. Radovits BJ, Kievit W, Fransen J et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1470-3.
12. Vermeer M, Kuper HH, Hoekstra M et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum 2011;63:2865-72.
13. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
14. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
15. Schmajuk G, Schneeweiss S, Katz JN et al. Treatment of older adult patients diagnosed with rheumatoid arthritis:improved but not optimal. Arthritis Rheum 2007;57:928-34.
16. Koike T, Harigai M, Inokuma S et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009;36:898-906.
17. Takeuchi T, Tatsuki Y, Nogami Y et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:189-94.
18. Komano Y, Tanaka M, Nanki T et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 2011;38:1258-64.
19. Sakai R, Komano Y, Tanaka M et al. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res 2012;64:1125-34.
20. Koike T, Harigai M, Inokuma S et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2011;21:343-51.
21. Koike T, Harigai M, Inokuma S et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan:interim analysis of 3881 patients. Ann Rheum Dis 2011;70:2148-51.
22. Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 2007;17:451-8.
23. Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007;357:1874-6.
24. Komano Y, Harigai M, Koike R et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 2009;61:305-12.
25. Tanaka M, Sakai R, Koike R et al. Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. Mod Rheumatol 2012;22:849-58.
26. Bruynesteyn K, Boers M, Kostense P, van der Linden S, van der Heijde D. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 2005;64:179-82.
27. Ishizaki T, Imanaka Y, Sekimoto M, Fukuda H, Mihara H. Comparisons of risk-adjusted clinical outcomes for patients with aneurysmal subarachnoid haemorrhage across eight teaching hospitals in Japan. J Eval Clin Pract 2008;14:416-21.
28. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies:post hoc analyses from the BeSt study. Ann Rheum Dis 2010;69:1333-7.
29. Kroot EJ, de Jong BA, van Leeuwen MA et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
30. Smolen JS, van der Heijde DM, St Clair EW et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
31. Welsing PM, Landewe RB, van Riel PL et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004;50:2082-93.
32. Takeuchi T, Yamanaka H, Ishiguro N et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Ann Rheum Dis 2014;73:536-43.
33. Kavanaugh A, Fleischmann RM, Emery P et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64-71.
34. Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119-25.
35. Emery P, Breedveld F, van der Heijde D et al. Two-year clinical and radiographic results with combination etanercept- methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 2010;62:674-82.
36. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784-92.
37. Radner H, Smolen JS, Aletaha D. Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology 2011;50:381-8.
38. Galloway JB, Hyrich KL, Mercer LK et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124-31.
39. Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, doubleblind, parallel treatment trial. Lancet 2008;372:375-82.
40. Dixon WG, Symmons DP, Lunt M et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904.
41. Koike T, Harigai M, Ishiguro N et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients:postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 2012;22:498-508.
42. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia:associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:628-34.
43. Dixon WG, Abrahamowicz M, Beauchamp ME et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012;71:1128-33.
44. Schneeweiss S, Setoguchi S, Weinblatt ME et al. Antitumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754-64.
45. Widdifield J, Bernatsky S, Paterson JM et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res 2013;65:353-61.
46. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
47. Verstappen SM, Jacobs JW, van der Veen MJ et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9.
48. Leirisalo-Repo M, Kautiainen H, Laasonen L et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator- initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis 2013;72:851-7.
49. Harris JA, Bykerk VP, Hitchon CA et al. Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian Early Arthritis Cohort. J Rheumatol 2013;40:1823-30.
50. Bakker MF, Jacobs JW, Welsing PM et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012;156:329-39.